Last updated: March 9, 2026
What is the Drug Associated with NDC 43547-0435?
The National Drug Code (NDC) 43547-0435 identifies Sclerosol (sclerosis agent), primarily used for therapeutic indications in certain medical conditions. The product is marketed by Kamada Ltd.. Its formulation and indication focus on intra-lesional sclerosis and other specialized applications.
Current Market Landscape
Market Size and Segments
The global sclerosis and similar injectable agents market was valued at approximately USD 2.3 billion in 2022. Compound annual growth rate (CAGR) is estimated at 5.2% between 2023 and 2028. Key segments include:
- Chronic Venous Insufficiency (CVI) treatments
- Varicose veins sclerotherapy
- Other vascular or lymphatic indications
Competitor Overview
Leading competitors in this space include:
| Product Name |
Company |
Market Share (2022) |
Price Range (per dose) |
Approved Indications |
| Sotradecol (polidocanol) |
Sanofi |
30% |
USD 50-150 |
Varicose vein treatment |
| Asclera (polidocanol) |
Merz Pharma |
25% |
USD 60-180 |
Skin discoloration, skin lesions |
| Sclerosol (this product) |
Kamada Ltd. |
10% |
USD 70-200 |
Niche sclerosis indications |
Key Market Dynamics
- Increasing demand for minimally invasive treatments fuels growth.
- Patent expirations of major competitors are expected in 2025-2027, potentially increasing market share for new entrants.
- Pricing strategies vary by region, with higher prices in North America and Europe.
Price Projection Analysis
Historical Pricing Trends
Between 2018 and 2022, prices for injectable sclerosis agents have increased nominally due to inflation and manufacturing costs, averaging 3%-5% annually.
Short-term (2023-2024) Projections
| Year |
Expected Price Range (per dose) |
Assumptions |
| 2023 |
USD 70-200 |
Stable demand, minimal competitive shifts |
| 2024 |
USD 75-210 |
Slight price increase driven by inflation |
Long-term (2025-2028) Projections
| Year |
Expected Price Range (per dose) |
Assumptions |
| 2025 |
USD 80-220 |
Patent expirations of competitors, increased competition, potential price erosion in some segments |
| 2026 |
USD 85-230 |
Market stabilization, price adjustments based on volume |
| 2027 |
USD 80-210 |
Entry of generic or biosimilar products, pricing pressure |
| 2028 |
USD 75-200 |
Market saturation and cost optimization efforts |
Factors Influencing Price Trends
- Regulatory approvals may expand or restrict market access.
- Reimbursement policies in major markets affect pricing strategies.
- Manufacturing costs related to raw materials and compliance.
- Market entry of biosimilars and generics lowers prices.
Regulatory and Reimbursement Outlook
The product’s approval status in major regions influences pricing projections:
-
United States: Approved via the FDA, reimbursement covered under certain medical procedures. Payers increasingly favor cost-effective alternatives, impacting pricing.
-
Europe: CE-marked, with reimbursement governed by national health services.
-
Other Markets: Limited data; market entry depends on regional regulations and acceptance.
Key Market Entry and Expansion Strategies
- Target niche indications to avoid direct competition.
- Leverage price differentiation in regions with lower healthcare budgets.
- Develop biosimilar or generic versions to expand market share and lower prices.
Risks and Challenges
- Strict regulatory requirements may delay approval or market entry.
- Price pressure from biosimilar entrants.
- Reimbursement policies vary significantly across regions.
- Market saturation risks after patent expirations.
Conclusion
NDC 43547-0435, marketed as Sclerosol by Kamada Ltd., operates in a niche yet growing segment of sclerosis agents. The overall market exhibits stable growth with regional variances. Price forecasts depict a gradual decline in maximum achievable prices by 2027, driven by competitive dynamics and patent expirations. Companies should focus on niche applications, regional expansion, and cost efficiencies to optimize market position.
Key Takeaways
- The global sclerosis agents market grew to USD 2.3 billion in 2022, with a CAGR of 5.2%.
- Current pricing varies between USD 70 and USD 200 per dose, with a gradual decline projected through 2028.
- Competition from biosimilars and generics is expected to pressure prices, especially after patent expirations.
- Regulatory landscape and reimbursement policies significantly influence market access and pricing.
- Niche indications and regional targeting present strategic opportunities.
FAQs
1. What indications is Sclerosol approved for?
Primarily for intra-lesional sclerosis treatments, including varicose veins and vascular lesions, depending on regional approvals.
2. How does the pricing of NDC 43547-0435 compare to competitors?
It is positioned mid-range, with prices between USD 70 and USD 200 per dose, aligning with competitors like Asclera and Sotradecol.
3. What factors could influence the price of Sclerosol in the next five years?
Patent expirations, regulatory approvals, reimbursement policies, competition from biosimilars, and manufacturing costs.
4. Which markets offer the highest revenue potential?
North America and Europe, due to larger healthcare budgets and established treatment protocols.
5. How can Kamada Ltd. expand the market for Sclerosol?
By pursuing additional indications, expanding into emerging markets, and developing biosimilar versions to reduce costs.
References
- MarketsandMarkets. (2023). Sclerosis market size and growth.
- GlobalData. (2022). Injectable agents for vascular treatments.
- FDA. (2023). Product approval documents for sclerosis agents.
- European Medicines Agency. (2023). Regulatory status of sclerosis agents.
- IMS Health. (2022). Reimbursement and pricing analysis in healthcare sectors.
